Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$23.38 +0.6%	$21.64	$12.21 ▼ $41.31	$682.80M	-0.26	634,580 shs	298,242 shs
HCM HUTCHMED	$15.34 -0.9%	$14.74	$11.51 ▼ $21.50	$2.70B	0.52	100,450 shs	22,921 shs
IMVT Immunovant	$16.39 +4.1%	$15.12	$12.72 ▼ $34.47	$2.69B	0.61	1.21 million shs	957,615 shs
OGN Organon & Co.	$9.99 -0.1%	$9.79	$8.01 ▼ $23.10	$2.60B	0.58	3.47 million shs	2.54 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	+0.60%	-0.04%	+16.15%	+23.38%	-3.47%
HCM HUTCHMED	-0.90%	-0.58%	+14.39%	+0.59%	-13.92%
IMVT Immunovant	+4.06%	+3.34%	+14.70%	-10.78%	-37.11%
OGN Organon & Co.	-0.13%	+1.02%	+9.51%	-31.20%	-51.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANAB AnaptysBio	2.1875 of 5 stars	3.4	0.0	0.0	0.0	3.8	1.7	0.6
HCM HUTCHMED	1.3568 of 5 stars	2.0	2.0	0.0	0.0	2.3	0.0	1.9
IMVT Immunovant	1.4077 of 5 stars	3.5	0.0	0.0	0.0	2.2	1.7	0.0
OGN Organon & Co.	4.7094 of 5 stars	3.3	2.0	1.7	3.7	1.7	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.80	Moderate Buy	$42.38	81.24% Upside
HCM HUTCHMED	2.00	Hold	$19.00	23.86% Upside
IMVT Immunovant	2.90	Moderate Buy	$38.33	133.88% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	80.23% Upside

Current Analyst Ratings Breakdown

Latest ANAB, IMVT, HCM, and OGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$22.00 ➝ $38.00
5/29/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
5/28/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $90.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/13/2025	HCM HUTCHMED	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/6/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $54.00
5/5/2025	OGN Organon & Co.	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $10.00
5/2/2025	OGN Organon & Co.	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Inline
5/1/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00
4/22/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$38.00 ➝ $17.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$91.28M	7.53	N/A	N/A	$2.33 per share	10.03
HCM HUTCHMED	$630.20M	4.24	$0.28 per share	53.89	$4.43 per share	3.46
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
OGN Organon & Co.	$6.40B	0.41	$4.92 per share	2.03	$1.83 per share	5.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$145.23M	-$4.85	N/A	N/A	N/A	-125.70%	-282.47%	-30.79%	8/4/2025 (Estimated)
HCM HUTCHMED	$37.73M	N/A	0.00	10.51	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	N/A	-80.60%	-71.89%	8/5/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.47	2.67	1.04	11.92%	227.43%	7.34%	8/5/2025 (Estimated)

Latest ANAB, IMVT, HCM, and OGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/5/2025	Q1 2025	ANAB AnaptysBio	-$1.30	-$1.28	+$0.02	-$1.28	$15.27 million	$27.77 million
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.80%	N/A	2.78%	N/A

Latest ANAB, IMVT, HCM, and OGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	8.25	8.25
HCM HUTCHMED	0.08	2.83	2.70
IMVT Immunovant	N/A	11.16	11.16
OGN Organon & Co.	16.49	1.67	1.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
HCM HUTCHMED	8.82%
IMVT Immunovant	47.08%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	33.50%
HCM HUTCHMED	3.60%
IMVT Immunovant	5.90%
OGN Organon & Co.	1.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	29.38 million	19.54 million	Optionable
HCM HUTCHMED	1,811	174.32 million	168.05 million	Not Optionable
IMVT Immunovant	120	170.92 million	160.84 million	Optionable
OGN Organon & Co.	4,000	259.96 million	254.86 million	Not Optionable

ANAB, IMVT, HCM, and OGN Headlines

Recent News About These Companies

OGN Investors Have the Opportunity to Lead the Organon Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

June 26 at 8:19 PM | prnewswire.com

OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit

June 26 at 5:02 PM | prnewswire.com

Organon & Co. Class Action: The Gross Law Firm Reminds Organon Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025 – OGN

June 26 at 4:39 PM | globenewswire.com

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit - OGN

June 26 at 9:00 AM | prnewswire.com

OGN SECURITIES: Lose Money on Organon & Co. (NYSE:OGN)? Contact BFA Law about the Pending Securities Fraud Class Action

June 26 at 8:36 AM | globenewswire.com

OGN - Organon & Co Ordinary Shares Valuation - Morningstar

June 25 at 12:48 AM | morningstar.comM

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN - Morningstar

June 25 at 12:48 AM | morningstar.comM

ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

June 25 at 12:25 AM | investing.com

ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

June 25 at 11:28 PM | globenewswire.com

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGN

June 25 at 6:15 PM | globenewswire.com

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

June 25 at 10:00 AM | zacks.com

Organon & Co. (OGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

June 25 at 9:00 AM | prnewswire.com

ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

June 24 at 11:08 PM | globenewswire.com

Investors who lost money on Organon & Co.(OGN) should contact Levi & Korsinsky about pending Class Action - OGN

June 24 at 4:16 PM | globenewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

June 24 at 11:32 AM | globenewswire.com

Organon & Co. (OGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

June 24 at 11:00 AM | prnewswire.com

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

June 24 at 10:44 AM | prnewswire.com

OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit with the Schall Law Firm

June 24 at 10:42 AM | prnewswire.com

Organon & Co. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights - OGN

June 24 at 9:00 AM | prnewswire.com

OGN STOCK LOSS: Organon & Co. Shareholders are Alerted of Imminent July 22 Class Action Deadline -- Contact BFA Law (NYSE:OGN)

June 24 at 8:18 AM | globenewswire.com

Organon & Co. (NYSE:OGN) Shares Purchased by Janney Montgomery Scott LLC

June 24 at 3:34 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB, IMVT, HCM, and OGN Company Descriptions

AnaptysBio NASDAQ:ANAB

$23.38 +0.14 (+0.60%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$23.41 +0.03 (+0.13%)

As of 04:34 AM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

HUTCHMED NASDAQ:HCM

$15.34 -0.14 (-0.90%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$15.32 -0.02 (-0.10%)

As of 06/26/2025 04:04 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Immunovant NASDAQ:IMVT

$16.39 +0.64 (+4.06%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$16.44 +0.05 (+0.34%)

As of 04:05 AM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Organon & Co. NYSE:OGN

$9.99 -0.01 (-0.13%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$9.99 +0.00 (+0.03%)

As of 04:33 AM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time